DUBLIN (AP) _ Jazz Pharmaceuticals PLC (JAZZ) on Tuesday reported a second-quarter loss of $363.3 million, after reporting a profit in the same period a year earlier.

On a per-share basis, the Dublin-based company said it had a loss of $6.11. Earnings, adjusted for pretax expenses and costs related to mergers and acquisitions, came to $3.90 per share.

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $3.55 per share.

The drugmaker posted revenue of $751.8 million in the period, also surpassing Street forecasts. Six analysts surveyed by Zacks expected $743.2 million.

Jazz expects full-year earnings in the range of $13.40 to $14.70 per share.

Jazz shares have risen roughly 4% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $171.50, an increase of 53% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on JAZZ at https://www.zacks.com/ap/JAZZ

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News